Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Restructuring (Tables)

6 Months Ended

Jun. 30, 2023

The amounts incurred in relation to the redundancy programme are as follows:


			One-time
	Contractual		employee		Total
	termination		termination		restructuring
	benefits		benefits		costs
Cumulative amount incurred to December 31, 2022	$	1,171	$	1,114	$	2,285
Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023		778		925		1,703
Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023	$	1,949	$	2,039	$	3,988

The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:


			One-time
	Contractual		employee		Total
	termination		termination		restructuring
	benefits		benefits		provision
Provision at January 1, 2023	$	1,171	$	1,114	$	2,285
Costs incurred and charged to General and administrative expenses		670		947		1,617
Costs paid during the period		(1,955)		(1,953)		(3,908)
Adjustments to the liability		108		(22)		86
Effect of foreign exchange rates		6		2		8
Provision at March 31, 2023	$	—	$	88	$	88

Costs paid during the period		—		(88)		(88)
Provision at June 30, 2023	$	—	$	—	$	—

The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:


	Three and six months ending
	June 30, 2023
Severance and other cash payments	$	5,655
Accelerated vesting of share-based compensation awards		835
Total and cumulative amount incurred to June 30, 2023	$	6,490


	Liability
Liability at June 1, 2023	$	805
Costs incurred and charged to Research and development expenses		1,267
Costs incurred and charged to General and administrative expenses		4,388
Costs paid during the period		(4,823)
Liability at June 30, 2023	$	1,637